Results 51 to 60 of about 30,645 (194)

Quantitative HBsAg and HBeAg predict hepatitis B seroconversion after initiation of HAART in HIV-HBV coinfected individuals. [PDF]

open access: yesPLoS ONE, 2013
OBJECTIVE: Anti-HBe seroconversion and HBsAg loss are important therapeutic endpoints in patients with hepatitis B virus (HBV) infection. Quantitative measures of hepatitis B surface antigen (qHBsAg) and e antigen (qHBeAg) have been identified as ...
Gail V Matthews   +11 more
doaj   +1 more source

Hepatitis B in Organ Transplantation—Current Evidence and Clinical Gaps

open access: yesTransplant Infectious Disease, EarlyView.
ABSTRACT Over the past several decades there have been significant advances in nucleos(t)ide analogue (NA) antiviral therapy for hepatitis B virus (HBV) and global expansion of primary prevention through immunization. Despite this, HBV remains a leading cause of chronic liver disease globally, affecting over 250 million people.
Oscar A. Fernandez‐Garcia   +3 more
wiley   +1 more source

Odds ratios of HBeAg seroconversion after 1-year treatment obtained through network meta-analysis.

open access: yes, 2017
Odds ratios of HBeAg seroconversion after 1-year treatment obtained through network meta-analysis.
Lin Cao (294505)   +3 more
core   +1 more source

HBsAg seroclearance in the chronic hepatitis B patients whom naïve and nucleos(t)ide analogue-treated: a long-term follow-up study

open access: yesThe Turkish Journal of Gastroenterology, 2019
This study was conducted in Trabzon Karadeniz Technical University Faculty of Medicine, Department of Infectious Diseases. Spontaneous HBsAg seroclearance is infrequent in adult HBV infection.
Iftihar Koksal   +2 more
doaj   +1 more source

Anti‐Viral Treatment Eligibility and Treatment Uptake Among People With Chronic Hepatitis B in Australia: The REACH‐B Study

open access: yesJournal of Viral Hepatitis, Volume 33, Issue 12, December 2026.
ABSTRACT Treatment indication for chronic hepatitis B (CHB) varies across clinical guidelines. This study evaluated treatment eligibility and uptake in a large Australian cohort of people with CHB. The REACH‐B study recruited people with CHB managed through a national network of healthcare services.
Behzad Hajarizadeh   +28 more
wiley   +1 more source

Estimated probabilities for each drug to be ranked for HBeAg seroconversion after 1-year treatment.

open access: yes, 2017
Estimated probabilities for each drug to be ranked for HBeAg seroconversion after 1-year treatment.
Lin Cao (294505)   +3 more
core   +1 more source

Forest Plot for HBeAg Seroconversion when IFN was used as the Control Group.

open access: yes, 2015
Forest Plot for HBeAg Seroconversion when IFN was used as the Control Group.
Qiao-Ling Xie (777501)   +4 more
core   +1 more source

Baseline and on-treatment HBcrAg levels as predictors of HBeAg seroconversion in chronic hepatitis B patients treated with antivirals

open access: yes, 2023
HBeAg seroconversion is an important treatment endpoint. We aimed to identify predictors of seroconversion using serum HBsAg and hepatitis B core-related antigen (HBcrAg) in HBeAg-positive patients treated with nucleos(t)ide analogs (NAs).
이현웅   +3 more
core   +1 more source

When Fat Goes Astray: Your Liver and Pancreas Get Into Trouble

open access: yesPortal Hypertension &Cirrhosis, Volume 5, Issue 3, Page 269-282, September 2026.
Metabolic dysfunction‐associated steatotic liver disease (MASLD) and intrapancreatic fat deposition (IPFD) are both common manifestations of ectopic fat accumulation. Although they share multiple risk factors, they also show notable differences in pathological features, standardization of diagnosis, and research maturity.
Yuying Chen   +5 more
wiley   +1 more source

Forest plot comparing the probability of HBeAg seroconversion between TDF and ETV.

open access: yes, 2019
Forest plot comparing the probability of HBeAg seroconversion between TDF and ETV.
Xu-wen Zheng (7907834)   +6 more
core   +1 more source

Home - About - Disclaimer - Privacy